Stempoint Capital’s Janux Therapeutics JANX Stock Holding History

Stempoint Capital’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-89,933	Closed	-$2.08M	–	92
2025 Q2	$2.08M	Sell	89,933 -252,129	-74%	-$6.64M	0.67%	38
2025 Q1	$9.24M	Buy	342,062 +196,186	+134%	+$7.4M	2.94%	10
2024 Q4	$7.81M	Buy	145,876 +96,461	+195%	+$5.1M	1.95%	18
2024 Q3	$2.24M	Sell	49,415 -43,534	-47%	-$1.89M	0.67%	35
2024 Q2	$3.89M	Sell	92,949 -28,693	-24%	-$1.35M	1.14%	29
2024 Q1	$4.58M	Buy	+121,642	New	+$2.65M	1.21%	24

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Stempoint Capital's JANX Position: Q3 2025 in Review

Stempoint Capital sold out of Janux Therapeutics (JANX) in Q3 2025, closing a stake of 89,933 shares — an estimated $2.08M sold.

Stempoint Capital first reported a position in JANX in Q1 2024 and held it in 6 quarters. The position peaked at $9.24M in Q1 2025. 174 funds tracked by Wall St. Rank hold JANX as of Q3 2025.

Stempoint Capital reported no remaining Janux Therapeutics position as of Q3 2025 after selling out during the quarter.
Stempoint Capital sold 89,933 Janux Therapeutics shares in Q3 2025, an estimated $2.08M.
Stempoint Capital first reported a position in Janux Therapeutics in Q1 2024 and held it in 6 quarters.
Stempoint Capital's Janux Therapeutics position peaked at $9.24M in Q1 2025.
174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2025.

Based on Stempoint Capital's 13F filing for Q3 2025, filed 14 Nov 2025.